<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02845375</url>
  </required_header>
  <id_info>
    <org_study_id>P16.025</org_study_id>
    <nct_id>NCT02845375</nct_id>
  </id_info>
  <brief_title>Effect of Neuromuscular Blockade and Reversal on Breathing</brief_title>
  <acronym>BREATH</acronym>
  <official_title>Effect of Neuromuscular Blockade and Reversal by Sugammadex Versus Neostigmine on Breathing When Hypoxic or Hypercapnic in Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators will assess (i) the effect of partial neuromuscular blockade
      (NMB; TOF ratio 0.8 and 0.6) induced by low-dose rocuronium on the ventilatory response to
      isocapnic hypoxia and (ii) the effect over time (from TOF 0.6 to TOF 1.0) of the reversal by
      sugammadex, neostigmine or placebo in healthy volunteers.

      Additionally the investigators will assess the effect of partial NMB (TOF ratio 0.6) induced
      by low-dose rocuronium on the ventilatory response to hypercapnia and effect over time (from
      TOF 0.6 to TOF 1.0) of the reversal by sugammadex, neostigmine or placebo in healthy
      volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The carotid bodies, located at the bifurcation of the common carotid artery, play a crucial
      and life-saving role in the control of breathing in humans. The carotid bodies contain type 1
      cells that are primarily sensitive to low oxygen concentrations in arterial blood. In
      response to low oxygen the carotid bodies send information to the brainstem respiratory
      centers and a brisk hyperventilatory response will be initiated ensuring an increase in
      uptake of oxygen via the lungs. Following surgery, a rapid return of the carotid body
      function is vital and persistent loss of carotid body function may result in respiratory
      complications that occur independent of the effects of anesthetics (incl. muscle relaxants)
      on respiratory muscles. Respiratory complications that are related to the loss of carotid
      body function include the inability to respond properly to hypoxia as well the inability to
      overcome upper airway obstruction. The latter is especially important in patients with sleep
      disordered-breathing and obese patients. These patients rely on the optimal function of their
      carotid bodies in response to hypoxia or upper airway closure.

      Important neurotransmitters involved in the carotid body response to hypoxia include
      acetylcholine, which acts through local nicotinergic acetylcholine receptors. Apart from the
      observation that muscle relaxants (which are blockers of the acetylcholine receptors) affect
      the proper functioning of the carotid bodies, the investigators have no knowledge on the
      dynamic effects of muscle relaxants on carotid body function over time or on the relationship
      between carotid body function and Train-of-Four (TOF) ratio over time. Additionally, there is
      no data on the link between the use of NMB antagonists and return of carotid body function.
      Linking TOF ratio to carotid body function is of clinical importance as a possible
      relationship will allow clinicians to predict carotid body function from the TOF ratio. The
      latter is highly relevant as the investigators show in a previous trial that a large
      proportion of patients is extubated at TOF ratio's &lt; 0.7.

      Apart from the carotid bodies, chemoreceptors in the brainstem exist that are sensitive to
      hypercapnia. This response system is not under control of cholinergic neurotransmission.
      Since the investigators may assume that the hypercapnic ventilatory response is not
      influenced by muscle relaxants the investigators can use this response to calibrate the
      hypoxic ventilatory response as both responses are equally affected by the effect of muscle
      relaxants on muscle function.

      As stated there is data on the effect of muscle relaxants on carotid body function at one
      fixed TOF ratio (TOF ratio fixed at 0.7). No data are available on:

        1. Dynamic effect of carotid body function as measured by the hypoxic ventilatory response
           at TOF ratio's slowly changing from 0.6 to 1.0;

        2. Dynamic effect of reversal of NMB by sugammadex versus neostigmine. Sugammadex and
           neostigmine are both reversal agents of neuromuscular blockade. At their institution the
           investigators use both agents in clinical practice but remain without knowledge on their
           effects on carotid body function. The current proposal is designed to study items 1 and
           2 in healthy awake volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2016</start_date>
  <completion_date type="Actual">September 1, 2018</completion_date>
  <primary_completion_date type="Actual">September 1, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Breathing Increase Due to a Reduction in Inspired Oxygen Saturation (Hypoxic Ventilatory Response)</measure>
    <time_frame>during the 1-2 hours following reversal</time_frame>
    <description>The change in breathing response to a decrease in inspired oxygen concentration, which equals the isocapnic ventilatory response to hypoxia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Breathing Increase Due to a Reduction in Inspired Oxygen Saturation (Hypoxic Ventilatory Response)</measure>
    <time_frame>0-10 minutes following reversal</time_frame>
    <description>The ventilatory response to a decrease in oxygen saturaytion of 80%</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Respiratory Insufficiency</condition>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (normal saline) will be administered following a period of muscle relaxation after which respiratory measurements will be obtained.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NEOSTIGMINE</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>intravenous neostigmine will be administered following a period of muscle relaxation after which respiratory measurements will be obtained.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SUGAMMADEX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intravenous sugammade will be administered following a period of muscle relaxation after which respiratory measurements will be obtained.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex</intervention_name>
    <description>Sugammadex will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.</description>
    <arm_group_label>SUGAMMADEX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine</intervention_name>
    <description>Neostigmine will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.</description>
    <arm_group_label>NEOSTIGMINE</arm_group_label>
    <other_name>NEO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.</description>
    <arm_group_label>PLACEBO</arm_group_label>
    <other_name>Normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male gender

          -  age 18 years and older

          -  body mass index &lt; 30 kg/m2.

        Exclusion Criteria:

          -  Known or suspected neuromuscular disorders impairing neuromuscular function;

          -  allergies to muscle relaxants, anesthetics or narcotics;

          -  a (family) history of malignant hyperthermia or any other muscle disease;

          -  any medical, neurological or psychiatric illness (including a history of anxiety).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <state>ZH</state>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Eriksson LI, Sato M, Severinghaus JW. Effect of a vecuronium-induced partial neuromuscular block on hypoxic ventilatory response. Anesthesiology. 1993 Apr;78(4):693-9.</citation>
    <PMID>8096684</PMID>
  </reference>
  <reference>
    <citation>Eriksson LI, Lennmarken C, Wyon N, Johnson A. Attenuated ventilatory response to hypoxaemia at vecuronium-induced partial neuromuscular block. Acta Anaesthesiol Scand. 1992 Oct;36(7):710-5.</citation>
    <PMID>1359723</PMID>
  </reference>
  <reference>
    <citation>Dahan A, Nieuwenhuijs D, Teppema L. Plasticity of central chemoreceptors: effect of bilateral carotid body resection on central CO2 sensitivity. PLoS Med. 2007 Jul 24;4(7):e239.</citation>
    <PMID>17676946</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 14, 2016</study_first_submitted>
  <study_first_submitted_qc>July 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2016</study_first_posted>
  <results_first_submitted>April 8, 2019</results_first_submitted>
  <results_first_submitted_qc>February 18, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 19, 2020</results_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Leiden University Medical Center</investigator_affiliation>
    <investigator_full_name>Albert Dahan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Pulmonary Valve Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>We will publish the paper. After publication the data are available</ipd_description>
    <ipd_time_frame>Mid 2019</ipd_time_frame>
    <ipd_access_criteria>Request to the authors and approved protocol for data analysis to be submitted. A review committee will then decide wether the data will be shared, deepening on supplementary data analyses by the authors</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 8, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT02845375/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 14, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT02845375/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>46 subjects were enrolled.6 did not meet inclusion citeria. 40 subjects were randomized</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>PLACEBO</title>
          <description>Placebo (normal saline) will be administered following a period of muscle relaxation after which respiratory measurements will be obtained.
Placebo: Placebo will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.</description>
        </group>
        <group group_id="P2">
          <title>NEOSTIGMINE</title>
          <description>intravenous neostigmine will be administered following a period of muscle relaxation after which respiratory measurements will be obtained.
Neostigmine: Neostigmine will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.</description>
        </group>
        <group group_id="P3">
          <title>SUGAMMADEX</title>
          <description>intravenous sugammade will be administered following a period of muscle relaxation after which respiratory measurements will be obtained.
Sugammadex: Sugammadex will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>upper airway obstruction</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PLACEBO</title>
          <description>Placebo (normal saline) will be administered following a period of muscle relaxation after which respiratory measurements will be obtained.
Placebo: Placebo will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.</description>
        </group>
        <group group_id="B2">
          <title>NEOSTIGMINE</title>
          <description>intravenous neostigmine will be administered following a period of muscle relaxation after which respiratory measurements will be obtained.
Neostigmine: Neostigmine will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.</description>
        </group>
        <group group_id="B3">
          <title>SUGAMMADEX</title>
          <description>intravenous sugammade will be administered following a period of muscle relaxation after which respiratory measurements will be obtained.
Sugammadex: Sugammadex will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20" lower_limit="19" upper_limit="29"/>
                    <measurement group_id="B2" value="23" lower_limit="18" upper_limit="29"/>
                    <measurement group_id="B3" value="23" lower_limit="19" upper_limit="25"/>
                    <measurement group_id="B4" value="22" lower_limit="18" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>All data were collectred during the screeing visit by an indpendent physician.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Sex</title>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Breathing response to a reduction in inspired oxygen concentration (hypoxic ventilatory response)</title>
          <units>L/min/% oxygen saturation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.66" spread="0.21"/>
                    <measurement group_id="B2" value="0.43" spread="0.23"/>
                    <measurement group_id="B3" value="0.54" spread="0.16"/>
                    <measurement group_id="B4" value="0.55" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Breathing Increase Due to a Reduction in Inspired Oxygen Saturation (Hypoxic Ventilatory Response)</title>
        <description>The change in breathing response to a decrease in inspired oxygen concentration, which equals the isocapnic ventilatory response to hypoxia.</description>
        <time_frame>during the 1-2 hours following reversal</time_frame>
        <population>Healthy male volunteers</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo (normal saline) will be administered following a period of muscle relaxation after which respiratory measurements will be obtained.
Placebo: Placebo will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.</description>
          </group>
          <group group_id="O2">
            <title>NEOSTIGMINE</title>
            <description>intravenous neostigmine will be administered following a period of muscle relaxation after which respiratory measurements will be obtained.
Neostigmine: Neostigmine will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.</description>
          </group>
          <group group_id="O3">
            <title>SUGAMMADEX</title>
            <description>intravenous sugammade will be administered following a period of muscle relaxation after which respiratory measurements will be obtained.
Sugammadex: Sugammadex will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.</description>
          </group>
        </group_list>
        <measure>
          <title>Breathing Increase Due to a Reduction in Inspired Oxygen Saturation (Hypoxic Ventilatory Response)</title>
          <description>The change in breathing response to a decrease in inspired oxygen concentration, which equals the isocapnic ventilatory response to hypoxia.</description>
          <population>Healthy male volunteers</population>
          <units>L/min/% desaturation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" spread="0.21"/>
                    <measurement group_id="O2" value="0.43" spread="0.22"/>
                    <measurement group_id="O3" value="0.54" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relaxation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" spread="0.22"/>
                    <measurement group_id="O2" value="0.29" spread="0.22"/>
                    <measurement group_id="O3" value="0.31" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reversal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.49" spread="0.13"/>
                    <measurement group_id="O2" value="0.36" spread="0.20"/>
                    <measurement group_id="O3" value="0.31" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Breathing Increase Due to a Reduction in Inspired Oxygen Saturation (Hypoxic Ventilatory Response)</title>
        <description>The ventilatory response to a decrease in oxygen saturaytion of 80%</description>
        <time_frame>0-10 minutes following reversal</time_frame>
        <population>The ventilation-saturation data were analyzed using linear regreassion analysis. The slope is the acute hypoxic ventilatory response.</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo (normal saline) will be administered following a period of muscle relaxation after which respiratory measurements will be obtained.
Placebo: Placebo will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.</description>
          </group>
          <group group_id="O2">
            <title>NEOSTIGMINE</title>
            <description>intravenous neostigmine will be administered following a period of muscle relaxation after which respiratory measurements will be obtained.
Neostigmine: Neostigmine will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.</description>
          </group>
          <group group_id="O3">
            <title>SUGAMMADEX</title>
            <description>intravenous sugammade will be administered following a period of muscle relaxation after which respiratory measurements will be obtained.
Sugammadex: Sugammadex will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.</description>
          </group>
        </group_list>
        <measure>
          <title>Breathing Increase Due to a Reduction in Inspired Oxygen Saturation (Hypoxic Ventilatory Response)</title>
          <description>The ventilatory response to a decrease in oxygen saturaytion of 80%</description>
          <population>The ventilation-saturation data were analyzed using linear regreassion analysis. The slope is the acute hypoxic ventilatory response.</population>
          <units>L/min/%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.49" spread="0.13"/>
                    <measurement group_id="O2" value="0.36" spread="0.20"/>
                    <measurement group_id="O3" value="0.48" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.299</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 day</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PLACEBO</title>
          <description>Placebo (normal saline) will be administered following a period of muscle relaxation after which respiratory measurements will be obtained.
Placebo: Placebo will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.</description>
        </group>
        <group group_id="E2">
          <title>NEOSTIGMINE</title>
          <description>intravenous neostigmine will be administered following a period of muscle relaxation after which respiratory measurements will be obtained.
Neostigmine: Neostigmine will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.</description>
        </group>
        <group group_id="E3">
          <title>SUGAMMADEX</title>
          <description>intravenous sugammade will be administered following a period of muscle relaxation after which respiratory measurements will be obtained.
Sugammadex: Sugammadex will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There were no perceived limitations or caveats</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Albert Dahan</name_or_title>
      <organization>Leiden University Medical Center</organization>
      <phone>+31715262301</phone>
      <email>a.dahan@lumc.nl</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

